Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Basics and Clinical Applications of Drug Disposition in Special Populations
| Basics and Clinical Applications of Drug Disposition in Special Populations |
| Autore | Amponsah Seth Kwabena |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2025 |
| Descrizione fisica | 1 online resource (483 pages) |
| Disciplina | 615.7 |
| Altri autori (Persone) | PathakYashwant |
| Soggetto topico |
Pharmaceutical Preparations - metabolism
Pharmaceutical Preparations - administration & dosage Pharmacokinetics Drug Monitoring - methods Drug Therapy - methods |
| ISBN |
9781394251292
1394251297 9781394251308 1394251300 9781394251315 1394251319 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Dedication -- Contents -- About the Editors -- List of Contributors -- Foreword -- Preface -- Chapter 1 Pharmacokinetic Principles and Concepts: An Overview -- 1.1 Introduction -- 1.2 Pharmacokinetic Parameters -- 1.2.1 Absorption -- 1.2.2 Distribution -- 1.2.3 Metabolism -- 1.2.4 Excretion -- 1.3 Pharmacokinetic Models -- 1.4 Applications -- 1.5 Conclusion -- References -- Chapter 2 Model-Based Pharmacokinetic Approaches -- 2.1 Introduction -- 2.1.1 Importance of PK -- 2.1.2 Overview of Model-Based Approaches -- 2.2 Basics of Pharmacokinetics -- 2.2.1 Key Pharmacokinetic Parameters -- 2.2.1.1 Absorption -- 2.2.1.2 Key Parameter -- 2.2.1.3 Distribution -- 2.2.1.4 Key Parameter -- 2.2.1.5 Metabolism -- 2.2.1.6 Key Parameter -- 2.2.1.7 Excretion -- 2.2.1.8 Key Parameter -- 2.2.2 Differences Between Traditional and Model-Based Pharmacokinetic Approaches -- 2.3 Pharmacokinetic (PK) Models -- 2.3.1 Introduction -- 2.3.2 Compartment Modeling -- 2.3.2.1 One-CompartmentModel -- 2.3.2.2 Multi-CompartmentModel -- 2.3.2.3 Two-CompartmentModel -- 2.3.3 Population PK Model -- 2.3.4 Physiologically Based PK (PBPK) Model -- 2.4 Model Development and Validation -- 2.4.1 Data Requirements for Model Development -- 2.4.2 Data Requirements for Model Validation -- 2.4.3 Steps in Model Building (E.g., Model Selection and Parameter Estimation) -- 2.5 Applications of Model-Based Approaches -- 2.5.1 Dose Optimization -- 2.5.2 Predicting Drug Interactions -- 2.5.3 Drug Tailoring in Special Populations (E.g., Pediatrics, Geriatrics, and Renal Impairment) -- 2.5.4 Translational PK from Preclinical to Clinical Settings -- 2.6 Modeling in Special Populations -- 2.6.1 Challenges and Considerations -- 2.6.1.1 Challenges in PK Modeling -- 2.6.1.2 Considerations in PK Modeling -- 2.7 Software and Tools for PK Modeling -- 2.7.1 Gastroplus™.
2.7.2 Berkeley Madonna -- 2.7.3 MATLAB -- 2.7.4 PK-Sim® -- 2.7.5 Simcyp® -- 2.7.6 Auxiliary PBPK Modeling Software -- 2.7.6.1 Julia -- 2.7.6.2 NONMEM -- 2.7.6.3 Phoenix WinNonlin -- 2.7.6.4 GraphPad Prism -- 2.7.6.5 Minitab -- 2.7.6.6 PlotDigitizer -- 2.7.6.7 GNU MCSim -- 2.7.6.8 WebPlotDigitizer -- 2.8 Regulatory Perspectives of PK Modeling -- 2.9 Future Directions of PK Modeling -- 2.10 Conclusion -- Abbreviations -- References -- Chapter 3 Physiologically Based Pharmacokinetic Modeling -- 3.1 Introduction -- 3.2 Significance of PBPK Modeling -- 3.3 Principles for the Development of PBPK for Special Populations -- 3.4 Data Integration for Special Populations -- 3.4.1 Demographic Data -- 3.4.2 Physiological Consideration -- 3.4.3 Ontogeny -- 3.4.4 Age and Maturation Changes -- 3.4.5 Steady State Volume of Distribution (Vdss) -- 3.5 Applications of PBPK Modeling -- 3.5.1 Dose Optimization/Regimen/Selection -- 3.5.2 Dose Individualization/Precision Dosing -- 3.5.3 Biopharmaceutics -- 3.6 Regulatory Applications/Pre-Post Market Utilization -- 3.7 Case Studies -- 3.7.1 Simulation Application -- 3.7.2 Successful Applications -- 3.8 Lessons Learned -- 3.9 Conclusion -- References -- Chapter 4 Therapeutic Drug Monitoring in Special Populations -- 4.1 Introduction -- 4.2 Pediatrics -- 4.2.1 Importance of TDM in Pediatrics -- 4.2.2 Pharmacokinetic Differences in Pediatric Patients -- 4.2.3 Drug Absorption in the Pediatric Population -- 4.2.4 Drug Distribution in the Pediatric Population -- 4.2.5 Drug Metabolism and Elimination in the Pediatric Population -- 4.3 TDM Practices in Pediatrics -- 4.3.1 Vancomycin -- 4.3.2 Aminoglycosides -- 4.3.3 Ganciclovir/Valganciclovir -- 4.3.4 Antiepileptic Drugs (AEDs) -- 4.3.5 Enoxaparin -- 4.4 Conclusion -- 4.5 Pregnancy -- 4.5.1 Physiological Adaptations in Pregnancy. 4.5.2 Current State of Clinical Practice of TDM in Pregnancy -- 4.5.3 TDM in Pregnancy -- 4.5.3.1 Antiepileptics -- 4.5.3.2 Antidepressants -- 4.5.3.3 Antiretroviral Drugs -- 4.5.3.4 Immunomodulatory Drugs -- 4.5.4 Challenges in the Implementation of TDM in the Pregnant Population -- 4.6 The Elderly -- 4.6.1 Physiological Changes in the Elderly -- 4.6.2 Effect of Aging on Drug Pharmacokinetics -- 4.6.3 Application of TDM in the Elderly -- 4.6.3.1 Cardiac Glycosides -- 4.6.3.2 Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) -- 4.6.3.3 Anticoagulants -- 4.6.3.4 Benzodiazepines -- 4.7 Conclusion -- 4.8 Hepatic and Renal Impairments -- 4.8.1 Hepatic Impairment -- 4.8.2 TDM in Patients with Hepatic Impairment -- 4.8.2.1 Meropenem -- 4.8.2.2 Metoprolol -- 4.8.2.3 Midazolam -- 4.8.3 Renal Impairment -- 4.8.4 Prerenal Disease -- 4.8.5 Intrinsic Renal Vascular Disease -- 4.8.6 Intrinsic Glomerular Disease (Nephritic or Nephrotic) -- 4.8.7 TDM in Renal Impairment -- 4.8.7.1 Vancomycin -- 4.8.7.2 Metformin -- 4.9 Conclusion -- 4.10 Overall Conclusion and Future Direction -- Acknowledgment -- References -- Chapter 5 Optimization of Drug Dosing Regimen -- 5.1 Introduction -- 5.2 Dosing Regimen Optimization Approaches and Strategies -- 5.2.1 Models Used for Dosing Regimen Selection -- 5.2.1.1 Pharmacometric Models -- 5.2.1.2 PK Models -- 5.2.1.3 Empirical Dose-Response Models -- 5.2.1.4 Multiple Comparison Procedures Models (MCP-Mod) -- 5.2.1.5 Model Averaging -- 5.2.2 Role of Patient Characteristics in Dose Selection -- 5.2.2.1 Phenotype-GuidedDosing -- 5.2.2.2 Genotype-GuidedDrug Dosing -- 5.2.3 Therapeutic Drug Monitoring (TDM) -- 5.3 Dosing Regimen in Special Populations -- 5.3.1 Dosing Regimen in Cancer Patients -- 5.3.1.1 Metronomic Chemotherapy -- 5.3.2 Dosing Regimen for Patients on Antimicrobial Therapy -- 5.3.2.1 Antimicrobial Stewardship Strategy. 5.3.2.2 Mathematical Models for Optimizing Antimicrobial Therapy -- 5.3.2.3 Antimicrobial Dosing Strategies During CRRT -- 5.3.2.4 Methods for Enhancing Dosing of Antimicrobials via Nebulization -- 5.3.3 Dosing Regimen in Pediatric Patients -- 5.3.3.1 Physiological Differences Between Pediatric and Adult Patients -- 5.3.3.2 Application of MIDD in Pediatric Dose Selection -- 5.3.3.3 Scaling from Adults to Pediatric Patients -- 5.3.3.4 Scaling from Animals to Pediatric Patients -- 5.3.3.5 Integrating Mechanistic Models in Neonates and Infants -- 5.3.3.6 Dose Optimization in Neonates and Infants -- 5.4 Conclusion -- References -- Chapter 6 Artificial Intelligence in Drug Development -- 6.1 Introduction -- 6.2 Application of AI in Drug Design -- 6.2.1 Target Identification and Validation -- 6.2.2 Drug Candidate Design and Optimization -- 6.2.3 Virtual Screening and Molecular Docking -- 6.2.4 Synthesis Planning -- 6.2.5 Predicting Drug Toxicity and Pharmacokinetics -- 6.2.6 Personalized Medicine -- 6.3 AI Use in Drug Formulation -- 6.4 Drug Release Characterization Using AI -- 6.5 AI-Based Dose/Dosing Regimen -- 6.6 Dissolution Rate Predictions with AI -- 6.7 Clinical End-Point Evaluation with AI -- 6.8 AI in Prediction of Fate of Drugs Administered Via Mucosal, Transdermal, and Parenteral Routes -- 6.9 AI-Integrated Mechanistic Modeling Platform for Drug Delivery and Monitoring -- 6.10 AI-Based Tools for Metabolism and Clearance Prediction -- 6.11 Limitations of Existing Tools -- 6.12 Conclusions -- 6.13 Conflict of Interest -- Acknowledgments -- References -- Chapter 7 Drug Disposition in Neonates and Infants -- 7.1 Introduction -- 7.2 Drug Absorption in Neonates and Infants -- 7.3 Drug Distribution in Neonates and Infants -- 7.4 Hepatic Metabolism of Drugs in Neonates and Infants -- 7.4.1 Phase I Metabolism -- 7.4.2 Phase II Metabolism. 7.5 Drug Excretion in Neonates and Infants -- 7.6 Pharmacodynamics in Neonates and Infants -- 7.7 Age-Related Dosing Regimen in Neonates and Infants -- 7.8 Conclusion -- References -- Chapter 8 Drug Disposition in Adolescents -- 8.1 Introduction -- 8.2 Physiological Considerations in Adolescents -- 8.2.1 Organ Development: Liver and Kidney Maturation -- 8.2.2 Variations in Body Composition -- 8.2.3 Hormonal Changes -- 8.2.3.1 Males -- 8.2.3.2 Females -- 8.2.4 Other Physiological Changes -- 8.3 Medication Adherence Challenges in Adolescents -- 8.4 Psychological Development on Drug Disposition -- 8.5 Risk-Taking behaviors and Their Implications on Medication Use -- 8.6 Drug Use Among Adolescents -- 8.6.1 Acetaminophen Use in Adolescents -- 8.6.2 Antidepressant Use in Adolescents -- 8.6.3 Drugs for ADHD -- 8.7 Pharmacokinetic Variability in Adolescents Drug Examples -- 8.7.1 Acetaminophen -- 8.7.2 Theophylline -- 8.7.3 Antidepressants -- 8.7.4 Drugs for ADHD -- 8.8 Legal and Ethical Considerations -- 8.8.1 Consent and Confidentiality in Adolescent Healthcare -- 8.8.2 Involving Adolescents in Treatment Decisions -- 8.8.3 Regulatory Aspects of Adolescents Drug Prescribing -- 8.9 Conclusion -- References -- Chapter 9 Drug Disposition in Pregnancy -- 9.1 Introduction -- 9.2 Physiological Changes in Pregnancy -- 9.2.1 Changes in Absorption -- 9.2.2 Changes in Distribution and Free Medication -- 9.2.3 Changes in Cytochrome Metabolism -- 9.2.4 Changes in Renal Excretion -- 9.2.5 General Considerations in Drug Dosing with Pregnancy -- 9.3 Placental Drug Disposition -- 9.3.1 Placental Barrier Anatomy and Physiology -- 9.3.2 Placental Transport Mechanisms -- 9.3.3 Methods of Study for Placental Drug Transfer -- 9.4 Drug Classification in Pregnancy -- 9.5 Pharmacokinetic (PK) Modeling -- 9.6 Physiologically Based Pharmacokinetic (PBPK) Modeling. 9.7 Limitations in PK and PBPK Models. |
| Record Nr. | UNINA-9911019742603321 |
Amponsah Seth Kwabena
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Rising Contagious Diseases : Basics, Management, and Treatments
| Rising Contagious Diseases : Basics, Management, and Treatments |
| Autore | Amponsah Seth Kwabena |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2024 |
| Descrizione fisica | 1 online resource (492 pages) |
| Disciplina | 616.9/8 |
| Altri autori (Persone) |
ShegokarRanjita
PathakYashwant V |
| Soggetto topico |
Communicable Diseases, Emerging - prevention & control
Communicable Disease Control - trends |
| ISBN |
1-394-18872-2
1-394-18874-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910829903003321 |
|
Amponsah Seth Kwabena
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Rising Contagious Diseases : Basics, Management, and Treatments
| Rising Contagious Diseases : Basics, Management, and Treatments |
| Autore | Amponsah Seth Kwabena |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2024 |
| Descrizione fisica | 1 online resource (492 pages) |
| Disciplina | 616.9/8 |
| Altri autori (Persone) |
ShegokarRanjita
PathakYashwant |
| Soggetto topico |
Communicable Diseases, Emerging - prevention & control
Communicable Disease Control - trends |
| ISBN |
1-394-18872-2
1-394-18874-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9911019227903321 |
|
Amponsah Seth Kwabena
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||